Evonik Expands Laurolactam Production in Response to High Demand

Key highlights
Related project For subscribers
Milestones, plant data, involved companies (owners, investors, licensors, contractors) and news — kept up to date.
Marl Evonik Laurolactam · Germany
Operational / Completed
2010-05
2012-01

Expansion Plans

Evonik Industries, based in Essen, Germany, is set to significantly expand laurolactam production capacities at its Marl site. The additional capacities are expected to be operational by the fourth quarter of 2010. This expansion is in response to the persistently high demand for polyamide 12.

Market Demand

Dr. Joachim Leluschko, head of Evonik’s High Performance Polymers Business Line, stated that the company is experiencing strong demand for its polyamide business. As a result, Evonik is taking steps to further expand its laurolactam production to meet this demand and secure its position as a reliable supplier in the market.

Product Information

Laurolactam is the starting material for polyamide 12, which Evonik markets under the brand names VESTAMID® and VESTOSINT®. These products are supplied to key markets globally, addressing specific customer needs and demands.

Global Reach

Evonik’s High Performance Polymers Business Line ensures the global availability of its high-performance polymers through a comprehensive sales network and service centers located in Europe, America, and Asia. The company also provides extensive technical support to its customers worldwide.

chemXplore Weekly

The week’s project milestones and project news from the chemical industry, free every Wednesday.

Free. One email a week. Unsubscribe any time.

Related articles

28 April 2026
Evonik opens Asia PAthletic Center for sports polyamide innovation

Offers R&D, ISO/ASTM testing, pilot processing, 3D samples and application support for long‑chain polyamides (PEBAs) to accelerate sports and consumer product commercialization

9 April 2026
Evonik showcases high-performance polymers and additives at CHINAPLAS 2026

Highlights materials for energy transition, EV battery cooling, eVTOL structures, hydrogen, smart manufacturing, 3D-printed medical implants, recycling additives and doubled PA12 capacity

1 August 2025
Evonik Reports Q2 Demand Decline

Q2 2025 saw a 12% EBITDA drop due to weak demand, currency effects, and divestments. Revenue fell 11%. Fewer shutdowns and new capacities expected to aid H2.